CEO Executive AssistantBiotech CEOs face a delegation challenge that is different from most industries: many of them built the science themselves. Founder-CEOs in particular came from the lab, understand the biology, and have deep intuitions about which programs will work. That scientific foundation is an asset in raising capital and in recruiting research talent. It becomes a liability when it prevents the CEO from delegating R&D decisions to the Chief Scientific Officer and research directors who are supposed to own them.
The stakes of getting this delegation wrong are high. Over-involved CEOs slow down scientific decision-making, create CSOs who cannot retain authority with their teams, and spend their own time on program-level decisions when they should be focused on pipeline strategy, partnerships, and investor relationships. Under-involved CEOs lose visibility into scientific risk until it surfaces as a clinical failure or a missed filing deadline.
This article provides a practical delegation framework for biotech CEOs: what to give your CSO full authority over, how to structure IND filing accountability, where partnership oversight lives, and which pipeline decisions stay at the CEO level.
The CEO-to-CSO Delegation Foundation
The most important delegation decision a biotech CEO makes in R&D is how much authority their Chief Scientific Officer actually has. In practice, many CSOs in biotech hold titles that do not match their decision rights. The CEO remains the scientific decision-maker, and the CSO is effectively a senior research manager.
This structure fails at scale. When your R&D organization grows beyond a point where one person can hold all the scientific context, you need a CSO who is genuinely empowered to make scientific decisions, build the research organization, and set the technical strategy within the pipeline priorities you have defined.
The CSO’s full authority should include:
Research organization structure and talent. How research teams are organized, what scientific disciplines you invest in, how research staff are recruited, developed, and managed. The CEO sets investment parameters (overall R&D budget, headcount targets); the CSO builds and manages the organization within them.
Experimental design and scientific methodology. How your research teams design studies, what models they use to validate findings, and what scientific standards govern data quality and reproducibility. This is core scientific judgment and belongs entirely to the CSO.
Program-level research decisions. Within the portfolio of programs the CEO has approved, the CSO owns decisions about how each program is prosecuted. Target validation strategies, lead optimization approaches, preclinical study design, and the scientific criteria for advancing candidates to IND-enabling studies are all CSO decisions.
Research partnerships and CRO relationships. Your CSO manages research-level collaborations with CROs, academic partners, and technology providers. Contracts at a certain value may require CFO and legal involvement; the scientific direction and vendor selection belong to the CSO.
Scientific publications and conference strategy. Decisions about what research to publish, when, and in which journals are scientific decisions with IP and competitive implications. The CSO makes these decisions with input from legal (IP protection) and corporate communications (timing and messaging).
Research Director Authority: Below the CSO Level
In a growing biotech organization, research directors or program directors lead individual discovery or development programs. Their delegation from the CSO mirrors the CEO’s delegation to the CSO: full authority within a defined scientific scope, with escalation triggers for decisions that cross program boundaries or carry portfolio-level implications.
Research directors should own:
- Day-to-day management of their program team, including hiring within headcount approvals
- Scientific progress against program milestones and go/no-go criteria
- CRO and academic collaborator management for their program
- Data package preparation for internal program reviews
- Communication with regulatory affairs on IND-enabling study requirements
Research directors should escalate to the CSO when:
- A program shows scientific signals that may affect go/no-go decisions
- Resource conflicts arise between programs that require portfolio-level arbitration
- A significant unexpected finding changes the scientific rationale for the program
- A vendor or academic partner issue cannot be resolved at the program level
The CSO handles most of these escalations independently. The CEO is rarely involved in research director escalations except when the escalation has portfolio-level pipeline implications.
IND Filing Accountability
Investigational New Drug applications represent a critical transition in the biotech development lifecycle: from research to clinical development, from animal to human, from scientific judgment to regulatory interaction. Getting the IND accountability structure right prevents the filing delays, quality failures, and regulatory surprises that derail programs and destroy timelines.
Who Owns the IND Filing
IND filings are cross-functional deliverables. The research team generates the preclinical data package. Regulatory affairs writes and assembles the IND. CMC (chemistry, manufacturing, and controls) contributes the drug substance and drug product sections. Toxicology contributes safety data summaries. The program leader coordinates the contributions.
In most mid-stage biotech organizations, IND filing accountability belongs to the Head of Regulatory Affairs (who owns the filing itself), the Program Director (who owns the integrated data package), and the CSO (who owns the go/no-go decision on IND readiness from a scientific standpoint).
The CEO does not own the IND filing process. The CEO’s role is to ensure the organization has the regulatory affairs capability and resources to file on schedule, to be informed when a filing timeline is at risk, and to make the call if a program-level decision (continuing versus pausing a program) is required that has pipeline-level implications.
IND Milestone Reviews
Build IND milestone reviews into your quarterly business reviews with the CSO. For each program approaching IND filing, the review should cover: completion status of IND-enabling studies, anticipated filing date, any outstanding data gaps or risk items, and CMC readiness. The CSO presents; you ask strategic questions. You are not reviewing the scientific data package.
When a milestone review flags that an IND is at risk (data gaps, manufacturing delays, regulatory concerns), the CSO owns the recovery plan. You are informed and involved in the decision if the recovery plan requires portfolio-level resource reallocation or investor communication about timeline changes.
FDA Pre-IND Meeting Decisions
For programs where a pre-IND meeting with FDA is warranted, the decision to request the meeting and the strategic framing of the meeting questions belongs to your Head of Regulatory Affairs and CSO. You may be briefed before a pre-IND meeting for a lead program. You should not be in the meeting room unless there is a specific strategic reason for CEO presence.
Partnership Collaboration Oversight
Research partnerships (academic collaborations, option agreements, co-development deals, platform access agreements) are a common source of delegation confusion in biotech. The business development team negotiates the deals. The CSO leads the scientific relationship. The CEO is sometimes in the middle, getting pulled into both the deal mechanics and the scientific collaboration.
Clarify the boundaries.
Deal negotiation and terms: Business development (or your CFO/legal team for smaller organizations) owns the commercial and legal terms. The CSO provides scientific input on deal structure (what data rights matter, what milestone triggers are scientifically appropriate, what IP ownership affects research strategy). The CEO approves deals above a defined value threshold. Below that threshold, the CSO and BD team handle it.
Ongoing collaboration management: Once a partnership is active, the CSO owns the scientific relationship with the partner. Joint research committee participation, data sharing, and collaborative publication decisions all sit with the CSO. The CEO is not involved in routine collaboration management.
Partnership health and strategic fit: The CSO should bring you a quarterly update on major active collaborations: scientific progress, relationship health, any issues threatening collaboration value, and any emerging opportunities within the collaboration that might warrant expanding scope. You are the strategic reviewer, not the operational manager.
Partnership escalation triggers: The CEO should be brought in when a partnership faces a relationship challenge that cannot be resolved at the CSO level, when a partner is signaling interest in acquisition or licensing discussions that go beyond research collaboration, or when a collaboration’s scientific output has pipeline implications that require portfolio-level decisions.
Pipeline Prioritization: The CEO’s Core Decision
The most important R&D decision the CEO makes is pipeline prioritization. Which programs get resourced and advanced, which programs are deprioritized or terminated, and how limited capital is allocated across the portfolio. This is not a delegation question; this is the CEO’s primary strategic responsibility in a biotech company.
Effective pipeline prioritization requires:
A portfolio review process. Hold a quarterly pipeline review with your CSO, Chief Medical Officer (if you have one), Head of Regulatory Affairs, and CFO. Each program is reviewed against scientific, clinical, regulatory, and financial criteria. The output is a portfolio-level view of where you are putting capital and why.
Clear go/no-go criteria for each program stage. Your CSO should develop go/no-go criteria for each major decision point in your development programs (IND filing, Phase 1 go/no-go, Phase 2 design approval, Phase 3 initiation). These criteria are the scientific and strategic standards that guide advancement decisions. Once established, your CSO can apply them operationally. You review the application of criteria for major advancement decisions and make the call when the data are ambiguous or when competitive or partnership factors complicate the scientific picture.
Capital allocation transparency. Your CFO and CSO should give you a clear view of how R&D capital is deployed across programs, functions, and stages at least quarterly. You cannot make good pipeline prioritization decisions without knowing where the money is going.
Termination discipline. The hardest pipeline decision in any biotech is to terminate a program. Scientific attachment, sunk cost bias, and team loyalty all create organizational resistance to termination. The CEO is the one who can make the termination call and absorb the organizational reaction. Your CSO should surface termination recommendations when the scientific case warrants it; you make and communicate the decision.
For biotech companies at the stage of filing regulatory submissions, the pharma CEO regulatory submissions playbook provides a complementary framework for how CEOs structure their involvement in NDA and BLA submission processes without creating bottlenecks in their regulatory affairs organization.
Building the Scientific Advisory Board Interface
Many biotech companies have Scientific Advisory Boards (SABs) that provide external scientific credibility and expert input. The CEO-SAB interface is a delegation question that often goes unresolved.
Your CSO should own the day-to-day management of the SAB: meeting scheduling, agenda development, data package preparation, and follow-up on SAB recommendations. The CEO should be present at SAB meetings and actively engaged with individual SAB members on the highest-priority strategic questions. You are not there to manage the SAB; you are there because your investors and partners treat SAB composition and engagement as a signal of scientific credibility.
When SAB members raise strategic concerns about your pipeline or scientific approach, those concerns should come to you through your CSO with the CSO’s assessment and recommended response. You are not managing SAB relationships at the advisory board member level unless those members are significant investors or partners.
The Scientific Founder Trap
If you are a scientist-founder CEO, the most important delegation insight in this article is this: your credibility as a scientist is not the same as your authority as a CEO. Both are real, and they are complementary. But they require different behaviors.
As a scientist, you evaluate hypotheses, design experiments, and hold opinions about biological mechanisms. As a CEO, you set portfolio strategy, allocate capital, build the executive team, and represent the organization to investors and partners. When you bring scientist behavior into CEO decisions, you slow down your CSO’s team, undermine their authority, and spend your most limited resource (your time and attention) on decisions that do not require CEO involvement.
The founders who build the most successful biotech companies are the ones who make this transition: staying deeply engaged with the science at the portfolio and strategy level, while delegating the day-to-day scientific judgment to a CSO who has the full authority the role requires. McKinsey research on biotech leadership transitions confirms that CEOs who successfully delegate scientific authority to a strong CSO while retaining pipeline prioritization decisions see faster development timelines and higher team performance. (See: McKinsey on biopharma R&D productivity).
Investor Relations and the R&D Narrative
Your investors are making decisions based on your pipeline. How you communicate R&D progress, setbacks, and strategy is a CEO responsibility that requires deep engagement with your CSO’s work. But the communication itself is yours.
Build a standing cadence with your CSO to review the R&D narrative before quarterly investor communications. You should be able to articulate the scientific rationale for each lead program, the key milestones that de-risk the pipeline, and the competitive differentiation of your approach. Your CSO gives you the content; you develop the investor narrative.
When a program fails, you own the communication. How you frame a clinical failure, what you disclose about the scientific learning, and how you position the path forward are CEO-level decisions that your scientific team informs but does not make.
Conclusion
R&D delegation in biotech is a high-stakes exercise in organizational trust. You need to give your CSO genuine authority over the scientific organization, or you will not be able to recruit and retain the scientific leadership your programs require. You need to stay closely engaged with pipeline strategy, capital allocation, and external scientific relationships, or you will lose the strategic insight that makes your CEO judgment valuable.
The biotech CEOs who build successful pipelines are not the ones who review every data package. They are the ones who hire excellent CSOs, build rigorous portfolio review processes, and make clear pipeline prioritization decisions that keep the organization focused on its highest-value programs. That is the delegation model that turns scientific potential into clinical and commercial outcomes. For more guidance, see our guide on pharma commercial delegation.
Related Reading
For further context, explore Delegation Strategies for Asset Management CEO and Delegation Strategies for Automotive CEO: Digital Retail.